Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). | LitMetric

A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 176

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML

File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). | LitMetric

Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).

David M Goldenberg Thomas M Cardillo Serengulam V Govindan Edmund A Rossi Robert M Sharkey

Oncotarget

Immunomedics, Inc., Morris Plains, NJ, USA.

Published: March 2020

[This corrects the article DOI: 10.18632/oncotarget.4318.].

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075468	PMC
http://dx.doi.org/10.18632/oncotarget.27512	DOI Listing

Publication Analysis

Top Keywords

correction trop-2

4

trop-2 novel

4

novel target

4

target solid

4

solid cancer

4

cancer therapy

4

therapy sacituzumab

4

sacituzumab govitecan

4

govitecan immu-132

4

immu-132 antibody-drug

4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!